Longitudinal follow-up of spirometry parameters in patients with COPD during pulmonary rehabilitation
<bold>Background:</bold> Spirometry is pivotal in the diagnosis and classification of COPD. There is limited data regarding variation in daily spirometry measurements in COPD. <bold>Objectives:</bold> This study investigated daily variation per week in spirometry parameters in patients with COPD during an 8-week inpatient pulmonary rehabilitation (PR) programme. <bold>Methods:</bold> Data of the first 30 participants of the ongoing “early diagnostic bioMARKers in Exacerbations of COPD” (MARKED) study (<ext-link>NCT05315674</ext-link>) in Ciro (Horn, The Netherlands) were analyzed. Spirometries were performed five days a week (Monday-Friday), during eight weeks. Values of the forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC ratio and peak expiratory flow (PEF) were captured. To test variations of daily spirometry results within individuals per week, during the eight-week PR period, the Friedman test and the post-hoc 2-way ANOVA analysis were performed, excluding dropouts. <bold>Results:</bold> At baseline, patients (60% males, aged 69±7.3 years) had an average of FEV1: 35.9±16.5% pred, FVC: 83.0±21.5% pred, FEV1/FVC: 33.6±10.4% and PEF: 57.4±15.8% pred. No significant differences in spirometry measurements were observed within individuals per week, during 8-week PR. Nine patients (30%) dropped out mainly due to the burden of daily spirometry (89%). <bold>Conclusions:</bold> This study demonstrated no significant differences in daily spirometry measurements within patients with COPD on a weekly basis during eight-weeks of PR. Results of the MARKED and other studies are needed to validate these findings.
Authors
- Sarah Houben‐Wilke (ORCID: https://orcid.org/0000-0001-6214-0365)
- Kristoffer Ostridge (ORCID: https://orcid.org/0000-0001-8910-3900)
- Frits M.E. Franssen (ORCID: https://orcid.org/0000-0002-1633-6356)
- Martijn A. Spruit (ORCID: https://orcid.org/0000-0003-3822-7430)
- Kiki Waeijen-Smit (ORCID: https://orcid.org/0000-0002-3737-7026)
- Victoria Godfrey (ORCID: https://orcid.org/0000-0003-4831-022X)
- Daphne Peerlings (ORCID: https://orcid.org/0000-0002-7449-4408)
- Antonio DiGiandomenico (ORCID: https://orcid.org/0000-0003-1745-647X)
- Sami O. Simons (ORCID: https://orcid.org/0000-0002-4296-5076)
- Sander M. J. van Kuijk (ORCID: https://orcid.org/0000-0003-2796-729X)
- Josh Woozley
Institutions
- Maastricht University Medical Centre (NL)
- Maastricht University (NL)
- AstraZeneca (Switzerland) (CH)
- AstraZeneca (Finland) (FI)
- Ciro (NL)
- AstraZeneca (Germany) (DE)
Publication Details
- Published
- 2024-09-14
- DOI
- https://doi.org/10.1183/13993003.congress-2024.pa3064
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00